The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice

Changes in treatment choice of therapy and size of treated population that can lead to under- or overestimate of payer's budget are less likely to be reassured after reimbursement adoption of a new drug. The aim of this study was to evaluate the effects of febuxostat introduction and the modifi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2019-08, Vol.14 (8), p.e0221504
Hauptverfasser:	Peng, Yueh-Lung, Lee, Chien-Te, Tain, You-Lin, Huang, Yaw-Bin, Chuang, Hung-Yi, Wen, Yen-Hsia, Huang, Shiou-Huei, Tsai, Chun-Yu, Hsu, Chien-Ning
Format:	Artikel
Sprache:	eng
Schlagworte:	Allopurinol Analysis Arthritis Autoregressive models Budgets Care and treatment Cost assessments Drugs Economic aspects Electronic health records Electronic medical records Engineering and Technology Febuxostat Febuxostat - economics Febuxostat - therapeutic use Female Future predictions Gout Gout suppressants Health care policy Health Expenditures Health insurance Hospitals Humans Hyperuricemia Insurance Insurance coverage Kidney diseases Male Materials management Medical records Medical research Medicine Medicine and Health Sciences Middle Aged Nephrology Patient outcomes Patients People and Places Pharmacy Practice Patterns, Physicians' - economics Practice Patterns, Physicians' - trends Prescription drugs Prescription Drugs - economics Prescription Drugs - therapeutic use Prevalence studies (Epidemiology) Professional associations Regression Analysis Rheumatism Risk factors Social Sciences Sulfinpyrazone Therapy Uric acid Uric Acid - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!